🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Healthcare Sector SEC Filings — September 04, 2026

The six filings are concentrated in three large healthcare companies—Elevance Health, Eli Lilly, and UnitedHealth Group—with all reported activity involving insider transactions rather than operating results, guidance, capital allocation, or M&A. The most material development is Johnson & Johnson MedTech executive Timothy Schmid's sale of 22,527 shares for approximately $6.19 million after option exercises and conversions; this is the only filing assigned negative sentiment and carries the highest materiality score of 7/10. Elevance Health reported tax-withholding transactions by two senior executives totaling 399 shares and approximately $164,500, while UnitedHealth CFO Wayne DeVeydt withheld 1,208.895 shares valued at approximately $483,000; these are generally administrative transactions and do not establish discretionary bearish conviction. Eli Lilly executives gifted 229 shares in aggregate, also a low-materiality activity with no clear directional signal. No period-over-period financial metrics, forward guidance, scheduled events, dividend or buyback data, transaction valuations, or financial-ratio trends were supplied, so no defensible cross-company growth, margin, valuation, or capital-allocation comparison can be made from this batch. The actionable distinction is between routine withholding/gifting activity and the substantially larger J&J MedTech disposition, which warrants monitoring but should not be treated as definitive evidence of deteriorating fundamentals without additional filings or operating disclosures.

6 high priority 6 total filings
· daily

US Earnings Financial Results SEC Filings — September 04, 2026

This batch of 24 filings reveals a market bifurcated between strong operational turnarounds and persistent cash-burn risks. Revenue growth is uneven, with standout performances from Snowflake (+35% YoY), Pure Storage (+37.8% YoY), and Victoria's Secret (+10.4% YoY), while several companies like Duluth Holdings (-7.8% YoY) and Virco Mfg (-5% YoY) face top-line pressure. A critical theme is aggressive capital allocation: share buybacks are surging at Abercrombie & Fitch ($286.4M in H1) and DocuSign ($625.3M in H1), often at the expense of cash reserves. Margin improvement is a key driver of earnings beats, with Victoria's Secret and Oxford Industries seeing gross margins expand significantly. However, the landscape is littered with high-risk micro-cap entities (Blue Chip Capital, Elite Performance) that are effectively insolvent, and several SPACs face mandatory liquidation deadlines. The most actionable insights come from comparing period-over-period trends in cash flow, insider activity, and forward guidance to separate genuine value creators from those masking structural issues with one-time gains.

24 high priority 24 total filings
· daily

US Executive Compensation Proxy SEC Filings — September 04, 2026

This digest of 11 pre-analyzed proxy filings reveals a bifurcated market landscape: while established firms like Paychex and Standex demonstrate robust financial health and disciplined capital returns, a cluster of smaller-cap companies (iBio, Grown Rogue, Jasper Therapeutics) are pursuing dilutive share increases or reverse splits, signaling distress. The most critical developments are two transformative M&A events—BioLife Solutions' acquisition by Repligen and Sanara MedTech's acquisition by MiMedx—both with materiality scores of 9-10/10 and shareholder votes imminent in late September. A notable trend across filings is the prevalence of 'mixed' sentiment (Paychex, Taylor Devices, Jasper, Sanara), where strong operational performance is offset by governance red flags like insider selling, missed bonus targets, or dilutive proposals. Insider activity data is sparse but revealing: Taylor Devices' CEO saw total comp drop 18% YoY, while Paychex's executives missed 36% of their target bonus, suggesting pay-for-performance discipline. The forward-looking catalyst calendar is dense, with five shareholder meetings scheduled between September 21 and October 26, 2026, creating near-term trading catalysts around M&A votes and governance decisions.

11 high priority 11 total filings
· daily

US IPO Pipeline SEC S-1 Filings — September 04, 2026

The September 4, 2026 IPO pipeline is dominated by three new S-1 registrations (Legion Capital Acquisition Corp., New Iceland Arctic Acquisition Corp., and ADARx Pharmaceuticals) and one S-4 for a SPAC merger (Churchill Capital Corp XI/Agility Robotics), alongside a high-risk IPO from Laser Photonics Corp. A clear bifurcation is emerging: cash-rich SPACs (New Iceland Arctic, $125M target) and biotech IPOs (ADARx) are pursuing high-growth narratives despite deep losses, while Laser Photonics offers a distressed, going-concern turnaround story. Period-over-period data reveals a stark divergence in financial health—ADARx's net loss widened 58% YoY to $73.1M, while Laser Photonics' revenue surged 144% YoY to $8.3M but losses exploded 600% to $17.5M. The most critical development is the Churchill Capital/Agility Robotics merger, which brings a high-profile robotics company to public markets via a SPAC, a structure that has faced significant headwinds. Portfolio-level patterns show a concentration of risk in pre-revenue biotech and cash-burning SPACs, with no insider trading activity disclosed in any filing, limiting conviction signals.

5 high priority 5 total filings
· daily

US SEC Trading Suspension Halt Orders — September 04, 2026

All six filings in this digest relate to US-listed companies facing trading suspensions or delisting risks, with a notable concentration in Nasdaq and NYSE American noncompliance notices. The primary theme is a wave of continued listing standard failures, driven by deteriorating balance sheets (negative or insufficient stockholders' equity) and share price declines. Five of the six companies (Nixxy, Arcadia, SCWorx, Matinas, Quince) have received deficiency notices, with SCWorx and Quince showing the most severe financial distress (public float 82% below minimum; equity $45M below threshold). Archer Aviation's warrant expiration is a scheduled event, not a financial distress signal, but it does create a specific trading catalyst. Across the group, there is a clear pattern of micro-cap biotech and tech companies struggling to maintain listing standards, with insider activity limited but notable in Nixxy (CFO appointment with equity incentives). The near-term catalyst calendar is dense, with compliance plan deadlines in mid-October 2026 for Arcadia and Quince, and a September 9, 2026 response deadline for SCWorx.

6 high priority 6 total filings
· daily

US Executive Officer Management Changes SEC — September 04, 2026

This digest covers 35 filings focused on executive and director changes, with the majority being routine departures and appointments. However, several filings contain material developments: The Bancorp's restructuring (9% workforce reduction, $14M annual savings) and Hooker Furnishings' governance failure (excess equity awards rescinded) are notable negative signals. Ategrity Specialty Insurance's significant executive compensation increase and Nordicus Partners' appointment of a highly experienced independent director are positive signals. A cluster of three BlackRock-affiliated funds (BlackRock Private Credit Fund, BlackRock Direct Lending Corp., BlackRock TCP Capital Corp.) all announced the simultaneous departure of Philip Tseng from multiple leadership roles, indicating a coordinated succession event. The overall theme is one of routine governance with isolated pockets of material change, particularly in the financial and industrial sectors.

35 high priority 35 total filings
· daily

US Corporate Board Director Changes SEC Filings — September 04, 2026

The September 4, 2026 batch of 35 SEC filings reveals a significant wave of board and C-suite changes across US-listed companies, with a notable concentration of departures and retirements rather than new appointments. The most critical development is the coordinated leadership transition at three BlackRock-affiliated credit funds (TCPC, BDEBT, BDLC), where Philip Tseng resigned from all director and CEO roles effective August 31, 2026, with Jason Mehring and Dan Worrell stepping up across all three entities—a rare synchronized reshuffle that signals a strategic shift in BlackRock's private credit leadership. Another high-materiality event is The Bancorp's restructuring, which eliminates 9% of its workforce and exits small business lending, generating $14M in annualized savings but incurring $5.6M in charges. The period-over-period comparisons are limited as most filings lack financial data, but insider activity patterns emerge: no insider buying was reported, while multiple departures (COO at SmartKem, CFO at Co-Diagnostics, CAO at Harrow) occurred without immediate replacements, suggesting potential operational gaps. Forward-looking data reveals a catalyst calendar with several key dates: Rambus CAO transition (Sept 8), Helix/Hornbeck merger-related equity awards (vesting by 2029), and Crown Holdings GC retirement (Dec 31). The overall sentiment is predominantly neutral (32/35 filings), with only one positive (Ategrity's CEO retention) and one negative (Hooker Furnishings' equity award error), indicating a routine but active period of governance reshuffling with limited immediate market impact.

35 high priority 35 total filings
· daily

USA Insider Trading Pulse — September 04, 2026

The September 4, 2026, insider trading pulse reveals a mixed but cautious landscape. The most significant bearish signal comes from PBF Energy, where a 10% owner sold ~$7.7M in stock, representing the largest single-day insider outflow. This is compounded by a cluster of negative sentiment filings from Sea Ltd, where two C-suite officers sold over $1.3M combined under 10b5-1 plans, and from Borr Drilling, where three top executives sold a total of ~$270K at a low stock price of $4.80. On the bullish side, insider buying was concentrated in micro-cap and distressed names, with the CEO of 17 Education & Technology Group and the COO of Charlotte's Web Holdings making notable open-market purchases. A strong positive signal emerged from Taiwan Semiconductor Manufacturing Co (TSMC), where an SVP bought $77K in shares, signaling confidence from a key insider at the world's leading foundry. The day was dominated by neutral, non-discretionary events, including a massive equity grant cycle at Protalix BioTherapeutics (awarding ~500K options and RSUs to the entire board and CEO) and tax-withholding transactions at Elevance Health and One Stop Systems. The overall theme is one of insider caution in larger caps and selective, high-conviction buying in smaller, beaten-down names, with a notable absence of bullish insider activity in mid-to-large cap growth stocks.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — September 04, 2026

This digest covers 15 filings, with a heavy concentration of SPAC activity including IPOs, business combinations, extensions, and compliance issues. The most material M&A events are the completed acquisitions of LivePerson by SoundHound AI and FSC Bancshares by Hawthorn Bancshares, and the combination of USA Rare Earth with Serra Verde. A clear theme is the acceleration of SPAC deadlines and the emergence of post-merger execution risks, particularly for companies like LivePerson, which underwent a going-private transaction. Insider activity is limited, but the appointment of LivePerson's former CFO at SoundHound AI signals integration focus. Capital allocation trends show a shift toward debt-free balance sheets post-merger, while several SPACs face existential risks from Nasdaq non-compliance or going-concern qualifications. The period-over-period data reveals no revenue trends due to the nature of filings, but forward-looking statements from SoundHound AI and Hawthorn Bancshares provide actionable revenue and operational targets.

15 high priority 15 total filings
· monthly

US Pre-Market SEC Filings Roundup — September 04, 2026

Overnight SEC filings from September 3-4, 2026, reveal a market bifurcated between high-conviction insider selling in growth/biotech names and significant corporate actions (M&A, spin-offs, restructurings). The most critical development is the FDA approval of Ionis Pharmaceuticals' ZANVASTRO for Alexander disease, a landmark event for an ultra-rare disorder, though offset by a mixed financial picture. A wave of insider selling, particularly at Natera, Spyre Therapeutics, and Takeda, signals potential near-term tops in these high-flying names. Activist pressure is building at TransAct Technologies, while corporate restructuring dominates headlines with Flex's spin-off and The Trade Desk's 15% workforce reduction. The IPO litigation settlement at Rent the Runway and the de-registration of RE/MAX highlight ongoing post-IPO and M&A fallout. Overall, the data suggests a cautious tone from corporate insiders, offset by significant strategic catalysts in biotech and energy.

39 high priority 11 medium 50 total filings
· daily

HHS & Healthcare Contracts Intelligence — September 03, 2026

The single $290.9 million firm-fixed-price contract awarded to Walgreens by the CDC under the ICATT program represents a fully obligated civilian health services win with high near-term revenue visibility through May 2025. This is a material, competitively awarded deal that underscores the CDC’s continued investment in specialized medical support infrastructure. However, the contract’s fixed-price structure carries medium execution risk, and the fully obligated nature means no further upside from option exercises. The bullish signal is strong at 7/10, but investors should monitor Walgreens’ ability to manage costs under this pricing model and track CDC budget allocations for the ICATT program in FY2025-2026 as a key renewal catalyst.

1 total filings
· daily

New Federal Contractors — September 03, 2026

This digest covers a single, large civilian contract awarded to Walgreens Boots Alliance by the Department of Health and Human Services (CDC) valued at $290.9 million. The contract is fully obligated and outlayed, providing high near-term revenue visibility for Walgreens through May 2025 under the ICATT program. The award was competitive and firm-fixed-price, offering margin upside potential but also execution risk. The key risk is the lack of defense exposure and the medium-term uncertainty around contract renewal or follow-on awards after May 2025.

1 total filings
· daily

Significant Contract Modifications ($10M+) — September 03, 2026

The sole contract in this period is a $290.9 million firm-fixed-price award from the CDC to Walgreens for specialized medical support under the ICATT program, representing 100% civilian agency spending. This fully obligated contract provides high near-term revenue visibility for Walgreens Boots Alliance through May 2025, with an estimated annual revenue contribution of $96.9 million. The award was won via full and open competition, signaling Walgreens' competitive strength in the public health services market. However, the fixed-price structure introduces execution risk, and the contract's concentration in a single program (ICATT) creates dependency on CDC budget priorities. Investors should monitor CDC's FY2025/FY2026 budget allocations and any follow-on award announcements for sustained growth.

1 total filings
· daily

Contract Deobligations Alert — September 03, 2026

This single-contract digest reveals a $290.9 million civilian award from the Department of Health and Human Services (CDC) to Walgreens, with zero defense-related activity. The contract, fully obligated and outlayed under the ICATT program, provides near-term revenue visibility for Walgreens Boots Alliance through May 2025. The bullish signal is tempered by medium execution risk from the firm-fixed-price structure and the absence of defense exposure, which limits sector-wide implications. Key watch items include Walgreens' cost management on this fixed-price contract and CDC budget allocations for FY2025-2026.

1 total filings
· daily

Contract Option Exercises — September 03, 2026

This digest covers a single, large civilian contract option exercise totaling $290.9 million, awarded to Walgreens Boots Alliance by the Department of Health and Human Services (CDC). The entire obligation is civilian, with no defense-related awards in the period. The highest-conviction signal is a bullish revenue visibility for Walgreens through May 2025, driven by a fully obligated firm-fixed-price contract for the ICATT program. However, the key risk is the fixed-price structure, which creates execution risk if costs overrun, and the medium-term uncertainty regarding contract renewal after May 2025.

1 total filings
· daily

All HHS Contracts — September 03, 2026

This single-contract digest covers a $290.9 million civilian award from the CDC to Walgreens under the ICATT program, with no defense-related content. The fully obligated, firm-fixed-price contract provides high near-term revenue visibility for Walgreens Boots Alliance through May 2025, but execution risk is material given the fixed-price structure on a service-intensive program. The dominant theme is stable civilian healthcare spending, specifically CDC's continued funding for specialized medical support services, with no cross-contract patterns or concentration beyond this single award. The highest-conviction signal is bullish for Walgreens due to full obligation and competitive win, though fixed-price risk and program dependency are key watch items.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — September 03, 2026

This digest covers a single $290.9 million civilian mega-contract awarded to Walgreens Boots Alliance by the CDC under the ICATT program, representing 100% non-defense spending. The contract is fully obligated and outlayed, providing high near-term revenue visibility through May 2025, but its firm-fixed-price structure introduces medium execution risk. The highest-conviction signal is the bullish revenue certainty for Walgreens, though the absence of defense exposure and the single-contract concentration limit broader sector implications. Key watch items include CDC budget allocations for ICATT in FY2025-2026 and potential competitor wins that could signal market share shifts.

1 total filings
· daily

High-Value Federal Grants ($5M+) — September 03, 2026

The sole contract in this period is a $290.9 million firm-fixed-price award from the CDC to Walgreens for specialized medical support under the ICATT program, marking a fully civilian (non-defense) transaction. This single-award stream shows a high-conviction bullish signal for Walgreens Boots Alliance, providing near-term revenue visibility through May 2025. The contract's full obligation and outlay reduce budget risk, but the fixed-price structure introduces execution risk, and the program's future depends on CDC budget allocations. Investors should monitor Walgreens' Q2 2025 earnings for renewal signals and track ICATT funding in FY2025-2026 appropriations.

1 total filings
· daily

General Federal Contracts — September 03, 2026

This digest covers a single, large civilian contract totaling $290.9 million, awarded to Walgreens Boots Alliance by the Department of Health and Human Services (CDC). The contract, which is fully obligated and outlayed, provides high near-term revenue visibility for Walgreens through May 2025 under the ICATT program. The highest-conviction signal is the bullish revenue certainty from this fully funded, firm-fixed-price award, though the fixed-price structure introduces medium execution risk. A key watch item is the potential for a follow-on contract or re-compete, which will be critical for sustaining this revenue stream beyond the current performance period.

1 total filings